Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
acute ocular pain epidemiology forecasts

SALE

Acute Ocular Pain - Epidemiology Forecast - 2034

Published Date : 2025

Pages : 101

Region : United States, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

Acute Ocular Pain Epidemiology

DelveInsight’s ‘Acute Ocular Pain (AOP) – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Acute Ocular Pain (AOP) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Canada, and South Korea.

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Canada
South Korea

Study Period: 2021-2034

Acute Ocular Pain (AOP): Disease Understanding

Acute Ocular Pain (AOP) Overview

The International Association for the Study of Pain (IASP) defines pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage,” and pain is commonly stratified into two broad groups—nociceptive and neuropathic pain. Nociceptive pain refers to the direct activation of nociceptors due to actual or threatened damage to non-neural tissue and implies an intact somatosensory nervous system. This is typically associated with transient pain following injury, surgery, or infection in the eye. In contrast, neuropathic pain is caused by a lesion or disease of the intrinsic somatosensory nervous system, often in the absence of other tissue injuries.

Ocular pain is a myriad of symptoms ranging from acute sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from straightforward refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. Most ophthalmologic conditions producing ocular pains are associated with symptoms and signs like red eye, photophobia, vision loss, or diplopia. Sometimes it poses a challenge to physicians when the pain is associated with a quiet or “white eye.”

Diagnosis of AOP is based on previous medical and medication history and physical examination of the eye, which is then confirmed by tests like computed tomography (CT), magnetic resonance imaging (MRI), histopathologic examination for the detection of cancers, and culture of the eye to check for a bacterial infection.

Approaches to treating ocular pain come from neuroscience, neurology, and pain management rather than the field of ophthalmology. Clinicians should be alert and attuned to the possibility that a patient might have a pain syndrome rather than a report of physiologic nociception. Symptoms are the manifestation of signaling and should be the focus of treatment. Continued signaling converts peripheral-to-centralized pain and acute-to-chronic pain, so the goal of ocular pain management must be to reduce signaling, and various research focusing on new therapeutic entities may reduce the conversion of acute-to-chronic pain is underway.

Epidemiology

The acute ocular pain (AOP) epidemiology division provides insights into the historical and current patient pool and the forecast trend of 6MM, Canada, and South Korea. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the number of cases of acute ocular pain (AOP) and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted acute ocular pain (AOP) epidemiology segmented as the number of cases of major eye disorders and the number of cases of acute ocular pain (AOP) in major eye disorders. The report includes the number of cases of acute ocular pain (AOP) scenario in the 6MM + Canada + South Korea from 2021 to 2034.

Country-wise Acute Ocular Pain (AOP) Epidemiology

The epidemiology segment also provides the acute ocular pain (AOP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Canada, and South Korea.

The total number of cases of acute ocular pain (AOP) in the 6MM + Canada + South Korea countries was more than 9 million cases in 2021.

As per the estimates, the US had the highest acute ocular pain (AOP) patient population in 2021. Among the EU5 countries, Germany had the highest number of cases of acute ocular pain (AOP), with over 1 million cases, followed by France in 2021. On the other hand, Spain had the lowest number of cases of acute ocular pain (AOP), with apprixmately 540,000 cases in 2021.

Scope of the Report

Acute Ocular Pain (AOP) report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
Acute Ocular Pain (AOP) epidemiology report and model provide an overview of the risk factors and global trends of acute ocular pain (AOP) in the 6MM, Canada and South Korea.
The report provides insight into the historical and forecasted patient pool of acute ocular pain (AOP) in 6MM, Canada, and South Korea.
The report helps recognize the growth opportunities in the 6MM, Canada, and South Korea concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of acute ocular pain (AOP).
The report describes acute ocular pain (AOP) epidemiology by the number of cases of major eye disorders in 6MM, Canada, and South Korea.
The report describes the epidemiology of Acute Ocular Pain (AOP) by the number of cases of acute ocular pain (AOP) in major eye disorders in 6MM, Canada, and South Korea.

Report Highlights

10-year forecast of acute ocular pain (AOP) Epidemiology
6MM, Canada, and South Korea Coverage
Number of cases of major eye disorders
Number of cases of acute ocular pain (AOP) in major eye disorders

KOL Views

We interview KOLs and obtain SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern, which will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

What major factors will drive the change in the patient population in acute ocular pain (AOP) during the forecast period (2025-2034)?
What key findings about acute ocular pain (AOP) epidemiology across 6MM, Canada, and South Korea, and which country will have the highest number of patients during the forecast period (2025-2034)?
What would be the total number of patients with acute ocular pain (AOP) across the 6MM, Canada, and South Korea forecast period (2025-2034)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2025-2034)?
At what CAGR is the patient population expected to grow in the 6MM, Canada, and South Korea forecast period (2025-2034)?
What are the disease risk, burdens, and unmet needs of acute ocular pain (AOP)?
What are the currently available treatments for acute ocular pain (AOP)?

Reasons to buy

The Acute Ocular Pain (AOP) epidemiology report will allow the user to:

Develop business strategies by understanding the trends shaping and driving the global acute ocular pain (AOP) market.
Quantify patient populations in the global acute ocular pain (AOP) market to improve product design, pricing, and launch plans.
Understand the magnitude of the acute ocular pain (AOP) population by the number of cases of major eye disorders in the 6MM, Canada and South Korea.
Understand the magnitude of the acute ocular pain (AOP) population by the number of cases of acute ocular pain (AOP) in major eye disorders in the 6MM, Canada and South Korea.
The acute ocular pain (AOP) epidemiology report and model were written and developed by Master and PhD level epidemiologists.
The acute ocular pain (AOP) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources.

Key Assessments

Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Acute Ocular Pain (AOP) Market Overview at a Glance

3.1. Market Share (%) Distribution of Acute Ocular Pain (AOP) in 2021

3.2. Market Share (%) Distribution of Acute Ocular Pain (AOP) in 2034

4. Executive Summary of Acute Ocular Pain (AOP)

5. Disease Background and Overview

5.1. Introduction

5.2. Clinical Manifestation

5.3. Causes

5.4. Pathogenesis

5.5. Diagnosis

5.5.1. Diagnostic algorithm

5.5.2. Differential diagnosis

5.6. Treatment

5.6.1. Treatment Guidelines

5.6.1.1. Guidelines for Dry Eye Disease (DED)

5.6.1.1.1. South Korean Guidelines for DED

5.6.1.2. Guidelines for Uveitis

5.6.1.2.1. European Guidelines for the Management of Uveitis Patients With an Inadequate Response to Non-corticosteroid Systemic Immunotherapy Therapy

5.6.1.2.2. American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

6.3. Assumptions and Rationale

6.4. Total Cases of Major Eye Disorders in the 6MM, Canada, and South Korea

6.5. Total Cases of Acute Ocular Pain (AOP) in the 6MM, Canada, and South Korea

6.6. The United States

6.6.1. Number of Cases of Major Eye Disorders in the United States

6.6.2. Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in the United States

6.7. The EU5

6.7.1. Number of Cases of Major Eye Disorders in the EU5

6.7.2. Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in the EU5

6.8. Canada

6.8.1. Number of Cases of Major Eye Disorders in Canada

6.8.2. Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in Canada

6.9. South Korea

6.9.1. Number of Cases of Major Eye Disorders in South Korea

6.9.2. Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in South Korea

7. Patient Journey

8. KOL Views

9. Unmet Needs

10. Acronyms and Abbreviations

11. Appendix

11.1. Bibliography

11.2. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

List of Tables:

List of Table

Table 1: Summary of AOP, Market, Epidemiology, and Key Events (2021-2034)

Table 2: Key Events

Table 3: History Findings Suggestive Different Causes of Eye Pain

Table 4: Physical Examination Findings Suggestive Different Causes of Eye Pain

Table 5: Differential Diagnosis of Eye Pain and Management

Table 6: Summary of Guidelines for DED

Table 7: Non-corticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis

Table 8: The total cases of acute ocular pain (AOP) in the 6MM, Canada, and South Korea in 000’s (2021-2034)

Table 9: The total cases of Acute Ocular Pain (AOP) in the 6MM, Canada, and South Korea in 000’s (2021-2034)

Table 10: Number of Cases of Major Eye Disorders in the United States (2021-2034)

Table 11: Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in the United States (2021-2034)

Table 12: Number of Cases of Major Eye Disorders in the EU5 (2019–20302)

Table 13: Number of Cases of Acute Ocular Pain in Major Eye Disorders in the EU5 (2021-2034)

Table 14: Number of Cases of Major Eye Disorders in Canada (2021-2034)

Table 15: Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders Canada (2021-2034)

Table 16: Number of Cases of Major Eye Disorders in South Korea (2021-2034)

Table 17: Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders South Korea (2021-2034)

List of Figures:

List of Figures

Figure 1: Clinical Signs of AOP

Figure 2: Corneal Disorders Causing AOP

Figure 3: Nociceptive Pathways

Figure 4: Diagnosing the Cause of Eye Pain

Figure 5: Treatment Recommendations According to the Severity Level of DED

Figure 6: Recommendations for Topical Glucocorticoids in Patients with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis

Figure 7: Total Cases of Major Eye Disorders in the 6MM, Canada, and South Korea (2021-2034)

Figure 8: Total Cases of Acute Ocular Pain (AOP) in the 6MM, Canada, and South Korea (2021-2034)

Figure 9: Number of Cases of Major Eye Disorders in the United States (2021-2034)

Figure 10: Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in the United States (2021-2034)

Figure 11: Number of Cases of Major Eye Disorders in the EU5 (2021-2034)

Figure 12: Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in the EU5 (2021-2034)

Figure 13: Number of Cases of Major Eye Disorders in Canada (2021-2034)

Figure 14: Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in Canada (2021-2034)

Figure 15: Number of Cases of Major Eye Disorders in South Korea (2021-2034)

Figure 16: Number of Cases of Acute Ocular Pain (AOP) in Major Eye Disorders in South Korea (2021-2034)

Tags:

License Type

Offer